Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 26% Improvement Relative Risk Progression 50% Unresolved fever 45% Unresolved dyspnea 29% Unresolved cough 41% O2 <92% 37% O2 <97% 20% c19early.org/t Asadirad et al. Curcumin for COVID-19 RCT LATE TREATMENT Is late treatment with curcumin beneficial for COVID-19? RCT 60 patients in Iran Lower progression (p=0.47) and improved recovery (p=0.094), not stat. sig. Asadirad et al., Phytotherapy Research, doi:10.1002/ptr.7375 Favors curcumin Favors control
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial
Asadirad et al., Phytotherapy Research, doi:10.1002/ptr.7375
Asadirad et al., Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of.., Phytotherapy Research, doi:10.1002/ptr.7375
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240 mg/day nano-curcumin for 7 days.
risk of death, 25.9% lower, RR 0.74, p = 0.74, treatment 5 of 27 (18.5%), control 6 of 24 (25.0%), NNT 15, excluding patients that stopped treatment due to progression - 3 for curcumin and 6 for control.
risk of progression, 50.0% lower, RR 0.50, p = 0.47, treatment 3 of 30 (10.0%), control 6 of 30 (20.0%), NNT 10.0.
risk of unresolved fever, 45.3% lower, RR 0.55, p = 0.09, treatment 8 of 27 (29.6%), control 13 of 24 (54.2%), NNT 4.1.
risk of unresolved dyspnea, 28.9% lower, RR 0.71, p = 0.72, treatment 4 of 27 (14.8%), control 5 of 24 (20.8%), NNT 17.
risk of unresolved cough, 40.7% lower, RR 0.59, p = 0.36, treatment 6 of 27 (22.2%), control 9 of 24 (37.5%), NNT 6.5.
risk of O2 <92%, 36.5% lower, RR 0.63, p = 0.51, treatment 5 of 27 (18.5%), control 7 of 24 (29.2%), NNT 9.4.
risk of O2 <97%, 20.0% lower, RR 0.80, p = 0.21, treatment 18 of 27 (66.7%), control 20 of 24 (83.3%), NNT 6.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Asadirad et al., 17 Jan 2022, Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: Received: 14 July 2021 Revised: 11 December 2021 Accepted: 22 December 2021 DOI: 10.1002/ptr.7375 RESEARCH ARTICLE Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial Ali Asadirad1,2 | Roohangiz Nashibi3 | Ali Khodadadi1,2 Mahvash Sadeghi1,4 | Azam Aminian2,5 | Sajad Dehnavi1 1 Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran | Ata A Ghadiri1 | Abstract The present study conducted a placebo-controlled clinical trial to evaluate the impact of 2 Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 3 Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 4 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 5 Department of Nursing, School of Nursing and Midwifery, Ilam University of Medical Sciences, Ilam, Iran Correspondence Sajad Dehnavi, Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: sjd72dehnavi@gmail.com Funding information Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Grant/Award Number: U-99051 1 | nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID19 patients. A total of 60 COVID-19 patients were randomly divided into nano-curcumin and control groups, and then they received 240 mg/day nano-curcumin for 7 days. The clinical manifestation and laboratory parameters in patients were recorded on days 0 and seven. Also, SYBR Green real-time PCR and ELISA techniques were implicated in assessing the mRNA expression of IFN-γ, IL-1β, IL-6, MCP-1, and TNF-α and the serum levels of IL1β, IL-6, and TNF-α inflammatory mediators, respectively. Although the clinical manifestations and laboratory parameters improved via the nano-curcumin treatment, the mRNA expression of IFN-γ (p = 0.006) and TNF-α (p = 0.04) were significantly reduced. Besides, a considerable difference was observed between the nano-curcumin and control groups in the expression of IFN-γ (p = 0.001), IL-1β (p = 0.0002), and IL-6 (p = 0.008). In addition, there was a significant difference between the nano-curcumin and control groups in the serum levels of IL-1β (p = 0.042). The evidence demonstrated that nano-curcumin could be implicated as a complementary medication to act as an antiinflammatory agent and inhibit inflammatory complications. KEYWORDS coronavirus disease-2019, curcumin, cytokine storm, inflammatory cytokines, severe acute respiratory syndrome-coronavirus-2 I N T RO DU CT I O N throat, fatigue, headache, nasal congestion, and gastrointestinal complications (G. Li et al., 2020). Also, some symptoms such as hypoxia, Coronavirus disease-2019 (COVID-19) is a newly emerged respiratory dyspnea, and difficulty breathing may be observed in patients with viral disease caused by the new coronavirus 2019 (2019-nCoV). This severe forms. This situation requires intensive care and mechanical new virus is also called severe acute respiratory syndrome- ventilation. Approximately 15% of patients progress to acute pneumo- coronavirus-2 (SARS-CoV-2). COVID-19 is characterized as a pan- nia, and in 5% of cases, this disease is accompanied by the acute..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit